Amgen Reports Combo Cuts Lung Cancer Death Risk 58%

BusinessCellectis Exits Two CAR-T Programs, Advances Gene Editing

Cellectis announced a strategic transformation to become an in vivo gene editing company, shifting resources to two lead programs HEAL-101 and HEAL-201 for severe dyslipidemias and exiting lasme-cel and eti-cel to extend its cash runway into the second half of 2028, while realigning its operating model around the in vivo pipeline. Phase 1 data are planned for HEAL-101 in the second half of 2027 and for HEAL-201 in the first half of 2028, with ongoing cell therapy partnerships and a September 14 conference call to discuss updates.

Read Full Article: https://ijr.com/discover/health-2026-10-24-amgen-reports-combo-cuts-lung-cancer-death-risk-58-836bd60c?utm_source=rss&utm_medium=syndication&utm_content=story_836bd60c-7dec-4b2d-97db-1fa7e1f93904